What cardiac side effects can Calquence (acalabrutinib) cause?
Calquence can affect the heart rhythm and, in some cases, cardiac function. Reported cardiac-related effects include irregular heartbeat and other cardiopulmonary symptoms seen with BTK inhibitors. Patients are commonly advised to get medical attention for new or worsening chest pain, fainting, severe dizziness, or shortness of breath. (Specific cardiac adverse-event rates vary by study and patient risk factors.)
Which heart rhythm problems should patients watch for?
Acalabrutinib has been associated with arrhythmias, including atrial fibrillation/flutter, as well as palpitations or irregular heartbeats. These can occur especially in people with cardiovascular risk factors or a prior history of rhythm disorders. If a patient develops sustained palpitations, rapid heartbeat, or symptoms like dizziness or near-fainting, they should contact their clinician promptly.
Can Calquence worsen heart failure or cause fluid-related symptoms?
Calquence can cause or worsen symptoms that may overlap with heart failure, such as shortness of breath, leg swelling, or rapid weight gain. Clinicians may consider holding or adjusting treatment if cardiopulmonary symptoms develop, particularly if they are new, progressive, or unexplained by other causes.
What symptoms should trigger urgent care?
Patients taking Calquence should seek urgent evaluation for severe or rapidly worsening cardiac or cardiopulmonary symptoms, including chest pain/pressure, fainting, severe dizziness, trouble breathing at rest, or signs of a serious rhythm disturbance (for example, sustained very fast or irregular heartbeat with weakness).
Who is at higher risk for cardiac complications on Calquence?
Risk may be higher in people with:
- Prior atrial fibrillation/flutter or other arrhythmias
- Significant heart disease (including coronary disease)
- Heart failure history
- Older age and cardiovascular risk factors (such as hypertension, diabetes, or prior stroke)
Clinicians typically weigh these factors when monitoring and may review baseline heart history and medications.
How are cardiac side effects managed if they happen?
Management often includes:
- Prompt assessment of symptoms and heart rhythm (often with ECG and, if needed, cardiac workup)
- Holding Calquence temporarily if a clinically significant event occurs
- Restarting at an adjusted dose or discontinuing depending on severity and recurrence
- Treating the underlying rhythm or heart condition (for example, standard arrhythmia management)
The exact approach depends on the event’s severity, persistence, and the patient’s overall cardiac status.
Can drug interactions increase cardiac risk?
Calquence is metabolized through drug-interaction pathways that can raise exposure to the drug when combined with certain medications. Higher exposure can increase the chance of adverse effects. Patients should tell their clinician about all prescription drugs, over-the-counter meds, and supplements so interactions can be checked.
What baseline monitoring is typically done before starting?
Clinicians often review cardiovascular history and may obtain baseline measurements such as an ECG in patients with cardiac risk factors or prior rhythm disorders. During treatment, they monitor for symptoms and may repeat ECG testing if palpitations or other rhythm symptoms occur.
What should patients ask their doctor during follow-up?
Patients can ask about:
- Whether they have risk factors for atrial fibrillation/flutter or other arrhythmias
- Whether they should get periodic ECG monitoring
- What symptoms should trigger dose interruption
- How their other cardiac medications might interact with Calquence
Sources
I don’t have the prescribing information or side-effect database contents needed to cite specific cardiac adverse-event statements for Calquence here. If you share the country/regulatory label (FDA/EMA/UK) or paste the relevant “Warnings and precautions/Adverse reactions” text, I can extract and summarize the exact cardiac side effects and their reported frequencies with precise citations.